Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oto-Laryngologica"
DOI: 10.1080/00016489.2022.2033317
Abstract: Abstract Background After treatment with an immune checkpoint inhibitor (ICI) is discontinued, retreatment with an ICI is a potential sequential treatment, but the clinical efficacy/safety data for this treatment of recurrent and/or metastatic head and… read more here.
Keywords: retreatment; metastatic head; niv cohort; treatment ... See more keywords